At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, reviews the clinical development of new chemotherapy-based approaches for the management of patients with advanced prostate cancer.
